JP2021534784A5 - - Google Patents

Info

Publication number
JP2021534784A5
JP2021534784A5 JP2021510693A JP2021510693A JP2021534784A5 JP 2021534784 A5 JP2021534784 A5 JP 2021534784A5 JP 2021510693 A JP2021510693 A JP 2021510693A JP 2021510693 A JP2021510693 A JP 2021510693A JP 2021534784 A5 JP2021534784 A5 JP 2021534784A5
Authority
JP
Japan
Prior art keywords
isolated polynucleotide
amino acid
cells
seq
sequence identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021510693A
Other languages
English (en)
Japanese (ja)
Other versions
JP7627080B2 (ja
JP2021534784A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/048814 external-priority patent/WO2020047257A1/en
Publication of JP2021534784A publication Critical patent/JP2021534784A/ja
Publication of JP2021534784A5 publication Critical patent/JP2021534784A5/ja
Priority to JP2025009061A priority Critical patent/JP2025066785A/ja
Application granted granted Critical
Publication of JP7627080B2 publication Critical patent/JP7627080B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021510693A 2018-08-31 2019-08-29 Ｂ７ｈ３キメラ抗原受容体を含む方法および組成物 Active JP7627080B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025009061A JP2025066785A (ja) 2018-08-31 2025-01-22 Ｂ７ｈ３キメラ抗原受容体を含む方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862725599P 2018-08-31 2018-08-31
US62/725,599 2018-08-31
PCT/US2019/048814 WO2020047257A1 (en) 2018-08-31 2019-08-29 Methods and compositions comprising b7h3 chimeric antigen receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025009061A Division JP2025066785A (ja) 2018-08-31 2025-01-22 Ｂ７ｈ３キメラ抗原受容体を含む方法および組成物

Publications (3)

Publication Number Publication Date
JP2021534784A JP2021534784A (ja) 2021-12-16
JP2021534784A5 true JP2021534784A5 (enExample) 2023-03-20
JP7627080B2 JP7627080B2 (ja) 2025-02-05

Family

ID=69643750

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021510693A Active JP7627080B2 (ja) 2018-08-31 2019-08-29 Ｂ７ｈ３キメラ抗原受容体を含む方法および組成物
JP2025009061A Pending JP2025066785A (ja) 2018-08-31 2025-01-22 Ｂ７ｈ３キメラ抗原受容体を含む方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025009061A Pending JP2025066785A (ja) 2018-08-31 2025-01-22 Ｂ７ｈ３キメラ抗原受容体を含む方法および組成物

Country Status (8)

Country Link
US (2) US12173071B2 (enExample)
EP (1) EP3844191A4 (enExample)
JP (2) JP7627080B2 (enExample)
CN (1) CN113039206A (enExample)
AU (1) AU2019333149B2 (enExample)
CA (1) CA3110858A1 (enExample)
IL (1) IL281129A (enExample)
WO (1) WO2020047257A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120093941A (zh) 2021-02-09 2025-06-06 苏州宜联生物医药有限公司 生物活性物偶联物及其制备方法和用途
EP4480499A1 (en) 2022-02-16 2024-12-25 Medilink Therapeutics (Suzhou) Co., Ltd. Conjugate of antibody-eribulin or derivative thereof, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and use thereof
EP4527415A1 (en) 2022-05-18 2025-03-26 Medilink Therapeutics (Suzhou) Co., Ltd. Antibody-drug conjugate containing protein degradation agent bioactive compound, method for preparing same, and use thereof
WO2024094165A1 (zh) * 2022-11-04 2024-05-10 茂行制药(苏州)有限公司 靶向b7h3的通用型car-t细胞及其制备方法和应用
WO2024106941A1 (ko) * 2022-11-15 2024-05-23 주식회사 셀랩메드 B7-h3 키메라 항원 수용체 및 이의 용도
AU2024263454A1 (en) * 2023-04-24 2025-12-11 Elpis Biopharmaceuticals Armored anti-b7h3 car-t cells and uses thereof in cancer therapy
CN119454937A (zh) 2023-11-13 2025-02-18 苏州宜联生物医药有限公司 抗b7h3抗体-药物偶联物治疗癌症的方法
WO2025235801A1 (en) 2024-05-08 2025-11-13 City Of Hope Antibodies targeted to osteopontin and uses thereof for reducing resistance of solid tumors immune cell therapy
CN119792297B (zh) * 2024-11-11 2026-05-05 中国人民解放军军事科学院军事医学研究院 PNP抑制剂Forodesine在治疗脑肿瘤中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US10155038B2 (en) * 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
JP5956342B2 (ja) 2009-11-03 2016-07-27 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 形質導入Ｔ細胞選択のためのトランケート上皮増殖因子レセプタ（ＥＧＦＲｔ）
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
PH12012501751A1 (en) * 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
LT2884999T (lt) * 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
US9790282B2 (en) * 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
US20160250258A1 (en) * 2013-10-31 2016-09-01 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
SG10201808811QA (en) 2014-04-10 2018-11-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Method and compositions for cellular immunotherapy
EP3288569A4 (en) * 2015-04-29 2018-12-19 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
EP3347375B1 (en) 2015-09-10 2020-12-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-cd276 chimeric antigen receptors
US20190112380A1 (en) * 2016-03-29 2019-04-18 University Of Southern California Chimeric antigen receptors targeting cancer
EP4166161B1 (en) * 2016-04-14 2026-03-04 Fred Hutchinson Cancer Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
EP3448874A4 (en) * 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
KR102742741B1 (ko) * 2017-10-18 2024-12-16 프레시전 인코포레이티드 스페이서를 포함하는 폴리펩타이드 조성물
WO2020010239A1 (en) * 2018-07-06 2020-01-09 The Board Of Trustees Of The Leland Stanford Junior University Chimeric antigen receptor polypeptides and methods of using same

Similar Documents

Publication Publication Date Title
AU2021232753B2 (en) T cell recruiting polypeptides based on TCR alpha/beta reactivity
CN113166262B (zh) Pd-1单结构域抗体及其治疗组合物
JP2022515318A5 (enExample)
JP2020178690A (ja) 多部分シグナル伝達タンパク質およびその使用
ES2701846T3 (es) Receptor de antígeno quimérico que usa dominios de reconocimiento de antígenos derivados de pez cartilaginoso
WO2022089353A1 (zh) 靶向bcma的单域抗体及其用途
CN112639102A (zh) 抗间皮素嵌合抗原受体(car)构建体及其用途
WO2018023025A1 (en) Combination therapies of chimeric antigen receptors adn pd-1 inhibitors
JP2020500530A5 (enExample)
CA3032581A1 (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
JP2015527070A5 (enExample)
JP2020530989A5 (enExample)
AU2018360800A1 (en) Chimeric antigen receptors specific for B-cell maturation antigen (BCMA)
JP2019532625A5 (enExample)
JP2019500891A5 (enExample)
JP2021518108A5 (enExample)
RU2015139874A (ru) ЛЕЧЕНИЕ РАКА С ИСПОЛЬЗОВАНИЕМ ХИМЕРНОГО АНТИГЕНСПЕЦИФИЧЕСКОГО РЕЦЕПТОРА НА ОСНОВЕ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ EGFRvIII
CN112638950A (zh) 一种双特异性抗体
TW202208415A (zh) Ｉｌ－１２裝甲的免疫細胞療法及其用途
WO2022247795A1 (zh) 靶向Claudin18.2的纳米抗体及其用途
FI4058474T3 (fi) Koostumuksia ja menetelmiä EGFR-positiivisten syöpien hoitoon
CN113891718A (zh) 人工免疫监视嵌合抗原受体(ai-car)及其表达细胞
WO2021027785A1 (zh) 共表达趋化因子受体的免疫效应细胞
JP2022539628A (ja) Ｈｐｖ ｅ６特異性およびｐｄ－１遮断性を有する二重機能性改変ｔ細胞
WO2025148750A1 (zh) 膜表达il-10及其用途